Antibiotic prophylaxis-Preventing severe infections and saving lives in poor countries with very high mortality risk

Keith P Klugman; Rasa Izadnegahdar

doi:10.1371/journal.pmed.1002594

Antibiotic prophylaxis-Preventing severe infections and saving lives in poor countries with very high mortality risk

PLoS Med. 2018 Jun 26;15(6):e1002594. doi: 10.1371/journal.pmed.1002594. eCollection 2018 Jun.

Authors

Keith P Klugman^{1

2}, Rasa Izadnegahdar²

Affiliations

¹ Pneumonia Program Strategy Team, Bill and Melinda Gates Foundation, Seattle, Washington, United States of America.
² Maternal Neonatal, Child Health Discovery and Tools Program Strategy Team, Bill and Melinda Gates Foundation, Seattle, Washington, United States of America.

Abstract

In a Perspective, Keith P. Klugman and Rasa Izadnegahdar from the Bill and Melinda Gates Foundation discuss the potentials and risks of antibiotic prophylaxis interventions for infectious disease outbreaks in rural regions, such as sub-Saharan Africa with very high mortality rates, when primary prophylactic vaccination programs are not yet available.

Publication types

Comment

MeSH terms

Africa South of the Sahara
Antibiotic Prophylaxis
Ciprofloxacin*
Humans
Meningitis, Meningococcal*

Substances

Ciprofloxacin

Grants and funding

The authors received no specific funding for this work, but wish to disclose that the MORDOR study was funded by the Bill and Melinda Gates Foundation.